Treatment Patterns and Use of Immune Checkpoint Inhibitors Among Patients with Metastatic Bladder Cancer in a Dutch Nationwide Cohort

Treatment Patterns and Use of Immune Checkpoint Inhibitors Among Patients with Metastatic Bladder Cancer in a Dutch Nationwide Cohort

Since 2017, two immune checkpoint inhibitors (ICIs) have become the standard of care for the treatment of metastatic urothelial carcinoma in Europe: pembrolizumab as second-line therapy and avelumab as maintenance therapy. Our aim was to describe the use of ICIs as first and later lines of treatment...

Full description

Bibliographic Details
Main Authors: Anke Richters, Debbie G.J. Robbrecht, Richard P. Meijer, Antoine G. van der Heijden, Lambertus A.L.M. Kiemeney, Joan van den Bosch, Britt B.M. Suelmann, Berna C. Özdemir, Niven Mehra, Katja K.H. Aben
Format: Article
Language:English
Published: Elsevier 2024-01-01
Series:European Urology Open Science
Subjects:
Metastatic bladder cancer
Urothelial cancer
Immune checkpoint inhibitors
Immunotherapy
Cohort study
Online Access:http://www.sciencedirect.com/science/article/pii/S2666168323025302

Internet

http://www.sciencedirect.com/science/article/pii/S2666168323025302

Similar Items